Zeylanica Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 25-05-2024
- Paid Up Capital ₹ 0.10 M
as on 25-05-2024
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 2670784.00%
(FY 2020)
- Profit -6248.04%
(FY 2020)
- Ebitda -3780.98%
(FY 2020)
- Net Worth -1771.48%
(FY 2020)
- Total Assets 1832.15%
(FY 2020)
About Zeylanica Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Trilochan Chawla, Harinder Chawla, Jaswinder Singh, and Three other members serve as directors at the Company.
- CIN/LLPIN
U51909GJ2017PTC097075
- Company No.
097075
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Apr 2017
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Zeylanica Pharmaceuticals?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Trilochan Chawla  | Director | 25-Apr-2017 | Current |
| Harinder Chawla | Director | 25-Apr-2017 | Current |
| Jaswinder Singh | Additional Director | 11-Jun-2019 | Current |
| Zeenat Mithiborwala | Additional Director | 03-May-2019 | Current |
| Jasminder Kaur | Additional Director | 03-May-2019 | Current |
| Manmohan Singh | Additional Director | 03-May-2019 | Current |
Financial Performance and Corporate Structure Insights of Zeylanica Pharmaceuticals.
Zeylanica Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 2670784% increase. The company also saw a substantial fall in profitability, with a 6248.04% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1771.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zeylanica Pharmaceuticals?
Unlock access to Zeylanica Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
19 years 7 months Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zeylanica Pharmaceuticals?
Unlock and access historical data on people associated with Zeylanica Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zeylanica Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zeylanica Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
